Non-melanoma skin cancer (NMSC), which includes basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), is the most common cancer in the United States and is responsible for significant economic costs ([@bib31]; [@bib27]). Although NMSC is more common among men than women, the incidence has rapidly increased for both genders ([@bib6]; [@bib31]). Well-established NMSC risk factors include ultraviolet radiation from sun or tanning bed exposure ([@bib11]; [@bib37]), increasing age ([@bib16]; [@bib21]), immunosuppression (particularly for SCCs) ([@bib24]), and light skin ([@bib18]).

In laboratory studies, statins (3-hydroxy-3 methylglutaryl coenzyme A, HMG-CoA reductase inhibitors) have appeared to protect against NMSC by causing apoptosis of keratinocytes by lowering cellular cholesterol levels ([@bib12]) and activating the RAFMEK (mitogen-activated protein kinase 1) pathway ([@bib40]). Furthermore, cholesterol depletion because of statin use has been shown to inhibit the Hedgehog signaling pathway ([@bib8]; [@bib9]), which is critical in the carcinogenesis of basal cell carcinoma ([@bib35]; [@bib38]). Statins have also been shown to inhibit cancer cells in animal models and *in vitro* ([@bib5]). However, statins also have immunomodulatory properties including increasing regulatory T cells, which may lead to an increased risk for NMSC ([@bib10]; [@bib20]; [@bib26]; [@bib13], [@bib14]). Additionally, statins have been associated with increased photosensitivity, which may be due to their effect on signal-transduction pathways leading to proinflammatory cytokines ([@bib41]).

Clinical studies have also reported inconsistent relationships between NMSC and statin use. Several large retrospective studies and a meta-analysis of randomised controlled trials (RCTs) found no significant relationship between statins and NMSC incidence ([@bib3]; [@bib2]; [@bib17]; [@bib23]). An analysis of three statin RCTs designed to examine cardiovascular outcomes also found no increased risk of skin cancer incidence ([@bib29]), whereas other studies (both observation and case--control) have found lower incidence of NMSC and/or overall skin cancer in statin users ([@bib4]; [@bib15]). On the other hand, several reviews and RCTs have found an increased incidence of NMSC and/or melanoma with statin use ([@bib32]; [@bib7]; [@bib22]).

To contribute further to this literature, we investigated the prospective relationship between NMSC and statin use among postmenopausal white women in the Women\'s Health Initiative (WHI) Clinical Trial (CT) and WHI Observational Study (OS). Given the high NMSC incidence, especially in older populations, and 2013 cholesterol management guidelines, which are expected to broaden statin use to ∼56 million people in the United States, including patients without known cardiovascular disease ([@bib34]), it is important to further understand this relationship.

Materials and methods
=====================

Design, setting, and participants
---------------------------------

The WHI was designed to study morbidity and mortality in postmenopausal women through a large OS and a set of CTs, including diet modification (DM), hormone therapy (HT), and calcium and vitamin D (CaD), as described previously ([@bib39]). In brief, women were recruited between 1993 and 1998 at 40 US clinical centres with the following eligibility criteria: age 50--79 years, postmenopausal, estimated survival of at least 3 years, and no plans to move away from the recruitment area within 3 years. The combined OS+CT multiethnic cohort included 161 808 women. For our analyses, we included only white women owing to the low number of skin cancer cases in other ethnicities, which reduced the analytic cohort size to 133 541. We then excluded participants who lacked follow-up time and medication information at baseline, had personal cancer history at baseline (including NMSC and melanoma), and were missing confounders in the scientific model; this resulted in a final cohort size of 118 357 women ([Figure 1](#fig1){ref-type="fig"}).

Measurement of exposures and confounders
----------------------------------------

For measurement of statin use, participants were instructed to bring prescription medication containers to the baseline screening interview. Medication names were entered into the database by interviewers. Statin use was also updated at years 1, 3, 6, and 9 for CT participants, and year 3 for OS participants using the same methodology. OS women were followed until year 6 and CT women were followed until year 9 because of low number of medication inventories due to study closeout.

Statins were defined as any HMG-CoA reductase inhibitors, and classified based on potency and lipophilicity/hydrophilicity according to a prior WHI study on statin use and melanoma ([@bib19]). Lipophilic statins included lovastatin, simvastatin, fluvastatin, and cerivastatin. Hydrophilic statins included atorvastatin, pravastatin, and rosuvastatin. Potency was defined as follows: low -- lovastatin, fluvastatin; medium -- pravastatin; high -- simvastatin, atorvastatin, cerivastatin, rosuvastatin. A small percentage (\<1%) of participants used more than one statin drug; among these participants, the analysis duration of statin use was equal to the duration for the drug used for the longest duration time.

Potential confounders were included as covariates in the scientific model and defined *a priori* based on hypothesised and established factors for NMSC development. Information on confounders was collected through baseline questionnaires, and included the following: age group at screening (50--59, 60--69, and 70--79), education (⩽high school diploma/GED, school after high school, college degree or higher), body mass index (BMI) (\<25, ⩾25--30, and \>30 kg m^−2^), smoking status (never, past, and current), vitamin D intake (\<200, 200--\<400, 400--\<600, and ⩾600 IU), solar irradiance of region in Langleys (300--325, 350, 375--380, 400--430, and 475--500), geographic region by latitude (Southern: \<35°N; Middle: 35--40°N, and Northern: \>40°N), total physical activity (METs per week, quartiles), current health-care provider (yes/no, as proxy for access to medical care), adjustment for assignment to CT (active *vs* placebo arms of DM, HT conjugated equine Oestrogens and oestrogen+progestin (E+P), and calcium+vitamin D (CaD) trials) or OS, use of oral contraceptives, and use of menopausal HT.

Classification of cases (follow-up and ascertainment)
-----------------------------------------------------

Non-melanoma skin cancer cases were self-reported through questionnaires (every 6 months for CT and every year for OS) and not centrally adjudicated. Basal cell carcinoma and SCC were not reported separately. Over 10.5 average years of follow-up through August 2009, 11 555 NMSC cases were identified: 1529 among statin users and 10 026 among non-statin users.

Statistical analysis
--------------------

The primary outcome of interest was development of first-ever NMSC. We used random-effects logistic regression models to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for NMSC incidence in relation to statin use, as time to diagnosis data was not available for self-reported data. A random-effects model allows us to appropriately model the correlation between women\'s repeated NMSC reports. We fit two models, age- and study-arm-adjusted and multivariable-adjusted, which adjusted for the confounders listed above. We fit several models estimating ORs for NMSC as a function of these parameters of statin use separately: (1) any statin use, (2) type of statin (as defined earlier in the Materials and Methods section), (3) statin potency, (4) statin category, and (5) duration of statin use in years (none, \<1, 1 to \<3, ⩾3, \<5, and ⩾5). The primary exposure of interest was any statin use, and all others were considered of secondary interest. As such, all secondary *P*-values were adjusted using the Bonferroni correction to control the family-wise error rate. Each *P*-value was multiplied by a factor of 4 to account for the four secondary exposures. All tests were two-sided and tested at the 0.05 level of significance.

In the primary model with any statin use as the exposure, we formally tested for effect modification in separate models for each potential effect modifier by using a Wald test to obtain an omnibus *P*-value for the statistical interaction term. We tested six prespecified variables: age (50--59, 60--69, 70--79 years), BMI (\<25, ⩾25--30, and ⩾30 kg m^−2^), smoking (never, former, and current), solar irradiance Langleys (⩽375 and \>375), and vitamin D intake (\<400 and ⩾400 IU).

As a *post hoc* sensitivity analysis, we analysed the relationship between NMSC and statin use at baseline using propensity score matching (PSM). Variables included for matching in the propensity score were defined *a priori* based on factors that may affect a participant\'s propensity for using statins, but were not likely to be affected by statin use itself: health status, age, access to regular medical, current health-care provider, recent pap smear, recent mammogram, income, occupation, education, marital status, physical activity, smoking, vitamin D use, use of oral contraceptives, use of postmenopausal hormonal therapy, solar irradiance in Langleys, latitude, US region, family history (skin cancer, other cancer, MI, diabetes, stroke), osteoporosis history, arthritis history, multivitamin use, history of fracture before the age of 55 years, and CT arms. Propensity was determined by modelling the likelihood of statin use at baseline as a function of the above variables using a logistic regression models. The predicted log ORs resulting from this model were used at propensities. We used these propensities in the Matching package ([@bib33]) in R to implement a 1 to 1 matching scheme where all baseline statin users were matched with a single baseline non-user with the nearest propensity for statin use. The PSM data set was then fit to a conditional logistic regression model grouping on matched pairs. All statistical analyses were completed using SAS 9.3 (SAS Institute, Cary, NC USA) or R 3.1.0 (R Foundation for Statistical Computing, Vienna, Austria).

Results
=======

The baseline characteristics of the study cohort are presented in [Table 1A](#tbl1A){ref-type="table"}, stratified by use of statins at baseline. In general, statin users were older, had higher BMI distributions, and were more likely to have a current health-care provider. Other baseline characteristics were similarly distributed between the two groups. At baseline, 7.5% of the cohort used statins (8.1% in OS and 6.7% in CT); this increased to 13.5% in the OS at year 3 and 18.6% in the CT at year 6 ([Table 1B](#tbl1B){ref-type="table"}). At baseline, the most commonly used statins in the WHI OS+CT were simvastatin (30.7%), followed by lovastatin (27.5%), pravastatin (22.3%), fluvastatin (12.0%), and atorvastatin (8.2%) ([Table 2](#tbl2){ref-type="table"}). Cerivastatin and rosuvastatin were not used at baseline (not on the market at that time) but were reported in follow-up questionnaires in subsequent years. Low potency statins were used by 39.0% of the cohort, compared with 22.2% for medium potency statins, and 38.8% of the cohort for high potency statins. Lipophilic statins were used by 69.8% of the cohort. The distribution of statin use characteristics was similar among OS and CT participants.

In our study cohort, any use of statins (primary hypothesis, as a time-varying variable) in the random-effects logistic regression model was associated with significantly increased NMSC incidence (OR 1.21; 95% CI: 1.07--1.35; [Table 3](#tbl3){ref-type="table"}). Secondary analyses were adjusted for multiple testing using the Bonferroni correction method as described in the Materials and Methods section. For the secondary hypothesis of statin type, increased risk was found only for lovastatin (OR 1.52; 95% CI: 1.08--2.16) and simvastatin (OR 1.38; 95% CI: 1.12--1.69). Low (OR 1.33, 95% CI: 1.02--1.74) and high potency statins (OR 1.20; 95% CI: 1.06--1.37) had an increased risk compared with non-statin users. Additionally, lipophilic statin users had a significant increase compared with non-statin users (OR 1.39; 95% CI: 1.18--1.64). There was no clear trend in duration of use; participants using statins for \<3 years had a significant increase in odds of NMSC compared with never users; however, those using statins for \>3 years were not significantly different compared with never users. In the secondary analyses, there was no statistically significant effect modification found for the relationship between any statin use and NMSC incidence for the prespecified subgroup (age, BMI, smoking, Langleys, vitamin D; [Table 4](#tbl4){ref-type="table"}).

As a *post hoc* sensitivity analysis, we conducted a PSM analysis to reanalyse the relationship between statin use and NMSC incidence, as detailed in the Materials and Methods section. This analysis matched women who used statins with women who did not use statins (but had a similar propensity to use statins), and compared the outcomes between the matched pairs. The PSM analysis was based on 'any statin use\' and cohort characteristics at study baseline, and did not find a significant relationship between NMSC incidence and statin use.

Discussion
==========

In our large cohort of postmenopausal white women, use of statins was associated with an increased incidence of all NMSC. In particular, after adjusting *P*-values to account for testing of multiple secondary hypotheses on statin type and potency, increased risk was found for lovastatin and simvastatin statin types only, which was consistent with our finding of an increased risk for lipophilic statins, low potency, and high potency statins. There was no clear association for duration of use. There was also no significant effect modification for the relationship between NMSC and statin use by age, BMI, smoking, Langleys, vitamin D use, or history of NMSC/melanoma. To our knowledge, this is the first study to examine the relationship between statin use and all NMSC in a prospective cohort setting.

Comparison with other studies
-----------------------------

The first two simvastatin trials suggested an association with NMSC seen more often in treatment groups ([@bib25]). Other prior clinical studies on the relationship between NMSC and statins have been somewhat limited and conflicting, ranging from no significant relationship (for either all NMSCs or BCC/SCC) ([@bib3]; [@bib2]; [@bib17]; [@bib23]), increased risk with statin use ([@bib32]; [@bib7]; [@bib22]; [@bib1]), to decreased risk with statin use ([@bib4]; [@bib15]; [@bib29]). Few prospective studies have been conducted to investigate the relationship between statin use and either BCC or SCC, particularly with as many participants and cases as our study. However, several large studies have suggested an increased risk of NMSC associated with statin use. One study that showed an increased risk with statin use and NMSC incidence was a meta-analysis of all cancers and statins (median RR 1.6, range 1.2--2, evidence strength moderate) ([@bib22]); this analysis included RCTs, cohort studies, and case--control studies. It was also reported that NMSC was observed more often in the treatment groups of two simvastatin trials, the Scandinavian Simvastatin Survival Study (4S) and the Heart Protection Study (HPS), with the relationship statistically significant if both studies were combined ([@bib32]; [@bib7]) This agrees with our finding of a substantial increase in NMSC risk being seen for simvastatin specifically. One record-linkage study of over 400 000 Finnish participants did not find an overall association with statin use and NMSC, but found an increased risk associated with pravastatin specifically ([@bib17]). A nationwide case--control study in Denmark also found significantly increased risk of BCC only with ever statin use among 38 484 cases (OR 1.09; 1.06--1.33), which the authors attributed to possible residual confounding ([@bib1]). A prior WHI analysis found no significant evidence for statin use as a risk factor for melanoma ([@bib19]). In addition to these reports, the relationship of NMSC with statin use has been assessed in retrospective and case--control studies with mixed results ([@bib4]; [@bib15]; [@bib2]; [@bib17]; [@bib1]).

One plausible biological mechanism for increased NMSC risk with statin use is immunomodulation leading to increased regulatory T cells ([@bib10]; [@bib20]; [@bib26]; [@bib13], [@bib14]). However, multiple molecular pathways have also been proposed for how statins could decrease NMSC risk ([@bib8]; [@bib12]; [@bib40]; [@bib9]; [@bib35]; [@bib38]), and alternative biological mechanisms warrant further study. The literature has also reported photosensitivity and cutaneous side effects associated with statins, which may be related to increased NMSC risk, although the mechanisms are also not well understood ([@bib30]; [@bib28]; [@bib36]).

Sensitivity analysis
--------------------

In a *post hoc* PSM analysis conducted as a sensitivity analysis, the use of statins was no longer found to be significantly associated with NMSC incidence. However, the PSM analysis examined outcomes of matched pairs based on a propensity to use statins rather than statin use itself. In contrast, the main analysis, which investigated actual statin use and adjusted for measures of health access, found a significant relationship between NMSC incidence and statin use. Additionally, the PSM analysis was based on characteristics at study baseline; however, statin use increased considerably during the course of the trial, which was accounted for in the main analysis only. The conflicting findings of the main analysis with the PSM analysis suggest other possible contributors to our findings of increased NMSC incidence with statin use, which may be related to characteristics of women with a propensity to use statins (including better medical surveillance and access to care). However, our main analysis and our sensitivity analysis using PSM accounted for measures of socioeconomic status including current health-care provider and education. A randomised trial of statin use would control for such characteristics of users and non-users.

Strengths and limitations
-------------------------

The strengths of this study include the large size and geographic distribution of cohort, prospective nature of the study (given the rarity of prospective studies on this relationship), large size of the cohort and number of NMSC cases, and detailed information on confounders and exposures including statin use (including duration and type). Although factors such as age, BMI, smoking, solar irradiance, and vitamin D intake did not significantly modify the relationship of NMSC with statin use, the fact that our study took these into account is another strength. Limitations of the study include the fact that the study was observational in nature, NMSC was self-reported (not centrally adjudicated) and not further broken down into BCC and SCC, time to event data was not collected, and statin use was self-reported and relatively low at baseline. In addition, we limited the analyses to white women because of the small sample size (and thus potential number of NMSC cases) in other ethnicities, limiting generalisability of the findings to ethnicities where NMSC is not as prevalent. We were also not able to fully adjust for sun exposure because of limitations in the data collection, but we adjusted for proxies of exposure including Langleys and geographic area. Additionally, the lack of duration--effect relationship found for statin use and NMSC incidence (particularly effect found for those treated \<1 year) points to the possibility of residual confounding.

Conclusions
===========

In conclusion, the use of statins was associated with increased NMSC risk in our cohort of postmenopausal white women. As statin use is likely to increase significantly in the future under the new statin use guidelines and NMSC is already the most common cancer in the United States, these results may be important and warrant further investigation. As these observations do not provide evidence of causality or that a side effect of statin use is increased NMSC, we are not suggesting changes in current statin recommendations. Regardless, preventive sun exposure measures (which have been shown to be protective against NMSC) should be recommended for statin users as well as non-users (including sunscreen, wearing protective clothing, and avoiding the sun during peak exposure times). Patients at high risk for NMSC because of personal/family history, medical comorbidities, or skin type may want to consider using a statin type that is less strongly associated with NMSC incidence. Further areas for investigation include studying this relationship in the setting of a randomised controlled trial (including the effects of specific statin types on BCC and SCC separately), the effect of protective sun exposure behaviors on this relationship, and the underlying biological mechanisms that may mediate increased NMSC risk from statin use.
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###### Baseline characteristics of the WHI OS+CT cohort

                                                                             **Statin use at baseline**   
  -------------------------------------------------------------------------- ---------------------------- --------------
  **Age group (missing *N*=0)**                                                                           
  \<50--59                                                                   39 519 (32.77)               1598 (16.44)
  60--69                                                                     54 232 (44.97)               5114 (52.62)
  70--79+                                                                    26 833 (22.25)               3007 (30.94)
  **Education (missing *N*=836)**                                                                         
  \<HS                                                                       4004 (3.34)                  477 (4.94)
  HS                                                                         20 824 (17.38)               2094 (21.69)
  \>HS                                                                       94 983 (79.28)               7085 (73.37)
  **Smoking status (missing *N*=1562)**                                                                   
  Never smoked                                                               59 758 (50.15)               4544 (47.41)
  Past smoker                                                                51 509 (43.23)               4495 (46.90)
  Current smoker                                                             7889 (6.62)                  546 (5.70)
  **Category of vitamin D intake (dietary+supplements) (missing *N*=250)**                                
  \<200                                                                      42 500 (35.31)               3302 (34.02)
  200--\<400                                                                 22 542 (18.73)               1683 (17.34)
  400--\<600                                                                 30 480 (25.33)               2627 (27.07)
  600+                                                                       24 826 (20.63)               2093 (21.57)
  **Alcohol consumption (missing *N*=814)**                                                               
  Non-drinker                                                                30 313 (25.30)               2898 (29.98)
  \<1 drink per week                                                         39 668 (33.11)               3347 (34.63)
  1--\<7 drinks per week                                                     33 876 (28.27)               2378 (24.60)
  7+ drinks per week                                                         15 966 (13.32)               1043 (10.79)
  **BMI category (missing *N*=1133)**                                                                     
  \<25                                                                       45 354 (37.94)               2458 (25.50)
  25--30                                                                     41 257 (34.52)               3870 (40.15)
  30+                                                                        32 920 (27.54)               3311 (34.35)
  **Physical activity (MET-hrs/week)**                                                                    
  ⩽2.3                                                                       27 365 (23.91)               2257 (23.88)
  \>2.3--8.3                                                                 27 613 (24.13)               2473 (26.16)
  \>8.3--17.8                                                                29 559 (25.83)               2504 (26.49)
  \>17.8                                                                     29 920 (26.14)               2219 (23.47)
  **Current care provider (missing *N*=1034)**                                                            
  Yes                                                                        112684 (94.20)               9508 (98.58)
  No                                                                         6940 (5.80)                  137 (1.42)
  **Hormone therapy status (missing *N*=99)**                                                             
  Never used                                                                 49.997 (41.49)               4322 (44.53)
  Past user                                                                  19 214 (15.95)               1739 (17.92)
  Current user                                                               51 287 (42.56)               3645 (37.55)
  **Oral contraceptive use (missing *N*=1)**                                                              
  Yes                                                                        51793 (42.95)                3369 (34.66)
  No                                                                         68798 (57.05)                6352 (65.34)
  **Langleys of exposure (missing *N*=0)**                                                                
  300--325                                                                   38 806 (32.18)               3328 (34.24)
  350                                                                        25 304 (20.98)               2084 (21.44)
  375--380                                                                   13 328 (11.05)               1048 (10.78)
  400--430                                                                   19 130 (15.86)               1399 (14.39)
  475--500                                                                   24 016 (19.92)               1860 (19.14)
  **Latitude region (missing *N*=0)**                                                                     
  Northern (\>40°N)                                                          58 087 (48.17)               4771 (49.09)
  Middle (\>37--40°N)                                                        23 045 (19.11)               1838 (18.91)
  Southern (⩽37°N)                                                           39 452 (32.72)               3110 (32.00)
  Baseline NSAID use (missing *N*=0)                                         46 498 (38.56)               5313 (54.67)
  **Skin reaction to the sun (missing *N*=64 041)**                                                       
  No change/tans but does not burn                                           21 963 (36.02)               2047 (38.72)
  Burns, then tans                                                           15 575 (25.54)               1183 (22.38)
  Burns, tans minimally                                                      16 499 (27.06)               1360 (25.73)
  Burns, does not tan                                                        6939 (11.38)                 696 (13.17)
  **Daily summer sun exposure as a child (missing *N*=62 950)**                                           
  \<30 min                                                                   1457 (2.35)                  128 (2.38)
  30 min to 2 h                                                              16 168 (26.09)               1433 (26.64)
  \>2 h                                                                      44 349 (71.56)               3818 (70.98)
  **Daily summer sun exposure as an adult (missing *N*=62 906)**                                          
  \<30 min                                                                   19 051 (30.73)               1905 (35.26)
  30 min to 2 h                                                              30 944 (49.91)               2610 (48.32)
  \>2 h                                                                      12 000 (19.36)               887 (16.42)
  **Sunscreen use (missing *N*=64 647)**                                                                  
  None                                                                       28 541 (47.23)               2569 (49.17)
  SPF 2--14                                                                  2988 (4.94)                  242 (4.63)
  SPF 15--24                                                                 18 308 (30.30)               1540 (29.47)
  SPF 25+                                                                    10 594 (17.53)               874 (16.73)
  **Calcium/Vitamin D Trial Arm**                                                                         
  Not randomised to CaD                                                      92 577 (76.77                7805 (80.31
  Intervention                                                               13 978 (11.59                963 (9.91
  Control                                                                    14 029 (11.63                951 (9.78
  **HT Trial Arm**                                                                                        
  Not randomised to HT                                                       100 203 (83.10)              8168 (84.04)
  E-alone intervention                                                       3686 (3.06)                  301 (3.10)
  E-alone control                                                            3703 (3.07)                  334 (3.44)
  E+P intervention                                                           6642 (5.51)                  478 (4.92)
  E+P control                                                                6350 (5.27)                  438 (4.51)
  **DM Trial Arm**                                                                                        
  Not randomised to DM                                                       83 681 (69.40)               7255 (74.65)
  Intervention                                                               14 755 (12.24)               967 (9.95)
  Control                                                                    22 148 (18.37)               1497 (15.40)
  OS cohort                                                                  69 189 (57.38)               6054 (62.29)

Abbreviations: BMI=body mass index; CaD=calcium and vitamin D; CT=Clinical Trial; DM=diet modification; E+P=oestrogen+progestin; HS=higher secondary; HT=hormone therapy; OS=Observational Study; WHI=Women\'s Health Initiative.

###### Percentage of WHI OS+CT cohort reporting statin use at study year

  **Cohort**   **Baseline (%)**   **Year 1 (%)**   **Year 3 (%)**   **Year 6 (%)**   **Year 9 (%)**
  ------------ ------------------ ---------------- ---------------- ---------------- ----------------
  *OS+CT*      7.5%               9.5%             12.9%            18.6%            5.1%
  *OS*         8.1%                                13.5%                              
  *CT*         6.7%               9.5%             12.2%            18.6%            5.1%

Abbreviations: CT=Clinical Trial; OS=Observational Study; WHI=Women\'s Health Initiative.

*Note*: WHI OS followed until Year 6 ayd WHI CT followed until Year 9 because of study close-out.

###### Baseline statin use characteristics of the WHI OS+CT

                            **OS (*****N*****=75 243)**  **CT (*****N*****=55 202)**    **OS+CT (*****N*****=131 872)**                 
  ------------------------ ----------------------------- ----------------------------- --------------------------------- ------- ------ -------
  Statin use at baseline               6054              8.1%                                        3665                6.7%     9719  7.5%
  **Type**                                                                                                                              
  Atorvastatin                          564              9.3%                                         229                6.2%     793   8.2%
  Fluvastatin                           722              11.9%                                        446                12.2%    1168  12.0%
  Lovastatin                           1565              25.9%                                       1104                30.1%    2669  27.5%
  Pravastatin                          1349              22.3%                                        819                22.3%    2168  22.3%
  Simvastatin                          1873              30.9%                                       1106                30.2%    2979  30.7%
  Cerivastatin                           0               0.0%                                          0                 0.0%      0    0.0%
  Rosuvastatin                           0               0.0%                                          0                 0.0%      0    0.0%
  ***Potency***                                                                                                                         
  Low                                  2273              37.6%                                       1521                41.5%    3794  39.0%
  Medium                               1345              22.2%                                        811                22.1%    2156  22.2%
  High                                 2436              40.2%                                       1333                36.4%    3769  38.8%
  ***Category***                                                                                                                        
  Lipophilic                           4150              68.6%                                       2638                72.0%    6788  69.8%
  Other                                1904              31.5%                                       1027                28.0%    2931  30.2%
  ***Duration***                                                                                                                        
  \<1 year                             1898              31.4%                                       1294                35.3%    3192  32.8%
  1--\<3 years                         2062              34.1%                                       1213                33.1%    3275  33.7%
  3--\<5 years                         1016              16.8%                                        598                16.3%    1614  16.6%
  5+ years                             1078              17.8%                                        560                15.3%    1638  16.9%

Abbreviations: CT=Clinical Trial; OS=Observational Study; WHI=Women\'s Health Initiative.

*Notes*: Cerivastatin and rosuvastatin are classified as high potency statins. Cerivastatin was classified as lipophilic and rosuvastatin as other. Neither statin was used by the cohort at baseline but both are reported in subsequent years.

###### ORs ratios for NMSC and statin use in the WHI OS+CT

                                                                **Age and study arm adjusted**   **Multivariable-adjusted**                                           
  --------------------------------------------- -------- ------ -------------------------------- ---------------------------- ------- ---------- -------------------- -------
  *Any statin use*[a](#t3-fn3){ref-type="fn"}                                                                                 0.101                                   0.002
   No                                            10 026  14.0   Ref                                                                      Ref                           
   Yes                                            1529   15.6   1.09                             0.98--1.21                            **1.21**   **1.07**--**1.35**   
  *Type of statin*                                                                                                            0.400                                   0.080
   None                                          10 026  14.0   Ref                                                                      Ref                           
   Atorvastatin                                   514    15.4   0.99                             0.85--1.16                              1.10         0.93--1.30       
   Fluvastatin                                    113    14.0   0.94                             0.64--1.39                              1.03         0.68--1.56       
   Lovastatin                                     192    15.6   **1.46**                         **1.06--2.01**                        **1.52**   **1.08**--**2.16**   
   Other[b](#t3-fn4){ref-type="fn"}                33    17.9   0.90                             0.49--1.66                              0.90         0.47--1.72       
   Pravastatin                                    241    15.4   0.99                             0.76--1.29                              1.05         0.78--1.39       
   Simvastatin                                    436    16.3   **1.25**                         **1.03--1.51**                        **1.38**   **1.12**--**1.69**   
  *Statin potency*                                                                                                            0.944                                   0.044
   None                                          10 026  14.0   Ref.                                                                     Ref.                          
   Low                                            305    15.0   1.22                             0.97--1.54                            **1.33**   **1.02**--**1.74**   
   Med                                            241    15.4   0.99                             0.77--1.27                              1.05         0.79--1.40       
   High                                           983    15.8   1.09                             0.96--1.22                            **1.20**   **1.06**--**1.37**   
  *Statin category*                                                                                                           0.108                                   0.001
   None                                          10 026  14.0   Ref.                                                                     Ref.                          
   Lipo                                           772    15.8   **1.22**                         **1.05--1.41**                        **1.39**   **1.18**--**1.64**   
   Other                                          757    15.4   0.99                             0.87--1.14                              1.10         0.95--1.28       
  *Duration of use*                                                                                                           1.000                                   0.116
   None                                          10 026  14.0   Ref.                                                                     Ref.                          
   \<1                                            417    15.3   1.12                             0.94--1.33                            **1.22**   **1.01**--**1.49**   
   1--\<3                                         558    15.7   1.11                             0.95--1.29                            **1.23**   **1.04**--**1.47**   
   3--\<5                                         291    15.6   1.01                             0.82--1.24                              1.11         0.88--1.38       
   5+                                             263    15.8   1.10                             0.88--1.37                              1.23         0.97--1.57       

Abbreviations: BMI=body mass index; CI=confidence interval; CT=Clinical Trial; NMSC=non-melanoma skin cancer; OR=odds ratio; OS=Observational Study; WHI=Women\'s Health Initiative.

Fully adjusted models were adjusted for age, study arm, educational attainment, BMI, smoking history, vitamin D consumption, sun exposure, physical activity, health-care provider, occupation, and hormone use history. Bold denotes significance.

Statin use is the primary hypothesis, tested at *α*=0.05. Analyses on statin type, potency, category, and duration were secondary hypotheses and adjusted for multiple testing using the Bonferroni method.

Includes cerivastatin and rosuvastatin. These statins were used by a very small percentage of women and never at baseline.

###### Effect modification for NMSC incidence and any statin use

  **Effect modifier**    ***P*****-value**
  --------------------- -------------------
  Age                          0.353
  BMI                          0.388
  Smoking                      0.979
  Langleys                     0.326
  Vitamin D category           0.063

Abbreviations: BMI=body mass index; NMSC=non-melanoma skin cancer.
